Clinical Trial Update: Tocilizumab for KSHV-Associated Multicentric Castleman Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of tocilizumab for KSHV-associated multicentric Castleman disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castleman Disease
• Multicentric Castleman Disease

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Castleman Disease, Multicentric Castleman Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-06-23